These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26762356)

  • 1. Amyloid plaques are still main target for Alzheimer's drugs.
    Hawkes N
    BMJ; 2016 Jan; 352():i214. PubMed ID: 26762356
    [No Abstract]   [Full Text] [Related]  

  • 2. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

  • 3. Solanezumab and the amyloid hypothesis for Alzheimer's disease.
    Le Couteur DG; Hunter S; Brayne C
    BMJ; 2016 Dec; 355():i6771. PubMed ID: 28034844
    [No Abstract]   [Full Text] [Related]  

  • 4. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Curative treatment of Alzheimer's disease is still missing--is amyloid plaque hypothesis the wrong starting point?].
    Tanila H
    Duodecim; 2015; 131(3):243-8. PubMed ID: 26245074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    Rubin R
    JAMA; 2021 Aug; 326(6):469-472. PubMed ID: 34287610
    [No Abstract]   [Full Text] [Related]  

  • 7. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
    Gamage KK; Kumar S
    J Neurosci; 2017 Apr; 37(17):4430-4432. PubMed ID: 28446659
    [No Abstract]   [Full Text] [Related]  

  • 8. Aducanumab (Aduhelm) for Alzheimer's disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1628):105-106. PubMed ID: 34543258
    [No Abstract]   [Full Text] [Related]  

  • 9. Aducanumab: look before leaping.
    Perlmutter JS
    Nat Med; 2021 Sep; 27(9):1499. PubMed ID: 34413517
    [No Abstract]   [Full Text] [Related]  

  • 10. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody drugs for Alzheimer's show glimmers of promise.
    Reardon S
    Nature; 2015 Jul; 523(7562):509-10. PubMed ID: 26223602
    [No Abstract]   [Full Text] [Related]  

  • 12. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 13. Why aducanumab is important.
    Cummings J
    Nat Med; 2021 Sep; 27(9):1498. PubMed ID: 34413516
    [No Abstract]   [Full Text] [Related]  

  • 14. Landmark Alzheimer's drug approval confounds research community.
    Mullard A
    Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
    [No Abstract]   [Full Text] [Related]  

  • 15. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
    Saxena U
    Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising Results in 18-Month Analysis of Alzheimer Drug Candidate.
    Abbasi J
    JAMA; 2018 Sep; 320(10):965. PubMed ID: 30208438
    [No Abstract]   [Full Text] [Related]  

  • 17. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stop Alzheimer's before it starts.
    McDade E; Bateman RJ
    Nature; 2017 Jul; 547(7662):153-155. PubMed ID: 28703214
    [No Abstract]   [Full Text] [Related]  

  • 19. Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease.
    Shin J
    Int J Geriatr Psychiatry; 2011 May; 26(5):546-8. PubMed ID: 21446001
    [No Abstract]   [Full Text] [Related]  

  • 20. Sting of Alzheimer's failures offset by upcoming prevention trials.
    Mullard A
    Nat Rev Drug Discov; 2012 Sep; 11(9):657-60. PubMed ID: 22935790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.